Search This Blog

Tuesday, June 16, 2026

Outlook Therapeutics' BLA resubmission in wet AMD accepted by FDA with Class 1 review

, PDUFA target July 29, 2026

https://finviz.com/stock?t=OTLK&p=d

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)